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We have studied the global risk of retinopathy in a Mediterranean population of type 2 diabetes mellitus (T2DM) patients,
according to clinical, biochemical, and lifestyle biomarkers.The effects of the oral supplementation containing antioxidants/omega
3 fatty acids (A/𝜔3) were also evaluated. Suitable participants were distributed into twomain groups: (1) T2DMG (with retinopathy
(+DR) or without retinopathy (−DR)) and (2) controls (CG). Participants were randomly assigned (+A/𝜔3) or not (−A/𝜔3)
to the oral supplementation with a daily pill of Nutrof Omega (R) for 18 months. Data collected including demographics,
anthropometrics, characteristics/lifestyle, ophthalmic examination (best corrected visual acuity, ocular fundus photographs,
and retinal thickness as assessed by optical coherence tomography), and blood parameters (glucose, glycosylated hemoglobin,
triglycerides, malondialdehyde, and total antioxidant capacity) were registered, integrated, and statistically processed by the SPSS
15.0 program. Finally, 208 participants (130 diabetics (68 +DR/62 −DR) and 78 controls) completed the follow-up. Blood analyses
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confirmed that the T2DMG+DRpatients had significantly higher oxidative stress (𝑝 < 0.05), inflammatory (𝑝 < 0.05), and vascular
(𝑝 < 0.001) risk markers than the T2DMG−DR and the CG. Furthermore, the A/𝜔3 oral supplementation positively changed
the baseline parameters, presumptively by inducing metabolic activation and ameliorating the ocular health after 18 months of
supplementation.
1. Introduction
Diabetes mellitus (DM), with a prevalence of logistic growth,
rises pandemic proportions. It has been estimated that over
170 million people worldwide are currently affected by DM
and it seems that these numbers will augment to over 360
million by 2030 [1]. A report on the incidence and prevalence
of type 2 diabetes mellitus (T2DM) in 11 European countries
showed that the age-adjusted/country-adjusted prevalence in
2004 was 10.2% in men and 8.5% in women and that these
inequalities were highly related to the bodymass index (BMI)
[2]. In Spain, DM represents a big health problem, due to
its prevalence of about 10% in the global population aged
30–89 years [3]. Number of diabetics among people aged 45
years or older in USA during 2012 was 24.6 million. Among
them there were 2.1 million more diabetic men than women.
The total (direct/indirect) estimated costs of DM in the same
timeframe were $245 billion, and after adjusting for age/sex
these data concluded that medical expenditures (in general)
were double among diabetics compared with the no diabetics
[4]. Other reports including large population collections also
concluded that men had a higher T2DM prevalence than
women [5, 6]. However, a more recent estimation of the risk
factors for cardiovascular diseases described that diabetic
women who smoke or are overweight develop cardiovascular
conditions more frequently than men, with the same risk
factors [7, 8].
Major diabetic complications are the result of a close
interaction between genes and a wide variety of environ-
mental factors. Diabetic retinopathy (DR), the microvascular
complication of DM, is responsible for the decreased vision
and blindness in young and middle-aged individuals. It has
been estimated that about 80%of the type 2 diabetics (T2DM)
and half of patients with type 1 DM (T1DM) develop DR
in some point between the diagnosis and 15th year or more
of the disease course [9, 10]. In this framework, it is well
acknowledged that DR appearmore frequently in T1DM than
in T2DM patients and that DR prevalence end points posi-
tively correlate with the length of time afflicted byDM, as well
as by the glycosilated hemoglobin (HbA1c), and hypertension
blood pressure (HBP) levels [11, 12].
The retina is particularly sensitive to hyperglycemia. It has
been shown that prolonged blood glucose elevation induces
striking changes in oscillatory potentials in the electroretino-
gram (ERG), increased implicit times in the multifocal ERG
(mtERG), and dyschromatopsia, whereas short-term hyper-
glycemia results in an overall decrease in the implicit times
and increase in the amplitudes of the mtERG [13]. Chronic
hyperglycemia induces retinal damage through different
mechanisms, such as activation of protein kinase C, polyol,
and hexosamine pathways, and/or generation of advanced
glycation end products (AGEs). Nevertheless, hyperglycemia
damages the endothelial cells and pericytes and increases
vascular permeability with rupture of the blood-retinal bar-
rier with the subsequent appearance of the retinal hypo-
xia processes, which, in turn, induces vascular endothelial
growth factor (VEGF) expression, among other proangio-
genic effectors [14, 15]. In this situation, independently of the
presence or not of DR, main objectives for implementing eye
care in diabetics have to include maximum nutritional and
metabolic control.
Glycemic dysfunction has been widely associated with
increased generation of reactive oxygen (O
2
) and nitrogen
species (ROS, RNS) [16, 17].These are continuously produced
in cells during metabolic processes. Eventually, the electrons
are transferred to molecular O
2
, by reducing this to H
2
O in
a reaction catalyzed by the cytochrome c oxidase, accounting
for almost 98% of the molecular O
2
used by our body:
O
2
+ 4e− + 4H+ 󳨀→ 2H
2
O (1)
It is known that 1-2% of the O
2
undergoes an incom-
plete reduction by the mitochondria, generating the reactive
oxygen species (ROS), very unstable forms such as the
superoxide anion (O
2
∙−), formed when O
2
is reduced by
an electron. However, this molecule rapidly dismutates to
form the hydrogen peroxide (H
2
O
2
) that can itself undergo
dismutation by a reaction that is catalyzed by the manganese
superoxide dismutase. The rate of production of O
2
/H
2
O
2
depends on the Ca2+ availability. Importantly, the presence of
transition metals, mainly iron, can induce H
2
O
2
to generate
the highly reactive hydroxyl radical OH∙−:
O
2
+ e− = O
2
−
+H+ = HO∙ +O
2
󳨀→ H
2
O
2
(2)
In fact, ROS/RNS originated from mitochondrial or
nonmitochondrial sources have been related to DM, such as
xanthine oxidase, NADPH oxidase, cyclooxygenase, lipoxy-
genase, cytochrome P450, and nitric oxide synthase. To
counteract the effects of ROS/RNS, our body depends on the
endogenous and exogenous antioxidants (AOX), including
the enzymes superoxide dismutase, catalase, glutathione
peroxidase, and glutathione reductase [18].
Nevertheless, ROS overproduction or its deficient
removal leads to vascular disorders that result in protein frag-
mentation, amino acids aggregation, membrane lipids alter-
ation, and/or nucleic acids injury. These described changes
may trigger cell damage and death. From the described
oxidative background important biomarkers can emerge,
and obviously these molecules can be determined in DM
patients, especially in those suffering chronic diabetes-related
complications [19, 20].
The retina is continuously exposed to light.Therefore reti-
nal cells live under chronic oxidative stress conditions, also
induced by the high O
2
requirements and the high O
2
partial
pressure from the underlying vessels of the choriocapillaris.
It has also to be considered that the photoreceptor outer seg-
ments are very rich in polyunsaturated fatty acids (PUFAs),
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Table 1: Inclusion and exclusion criteria for the study participants. Criteria for eligibility in the Valencia Study on Diabetic Retinopathy
(VSDR).
Inclusion
Males and females, aged >25 years and <80 years with type 2 diabetes for 12 months (at least)
Insulin na¨ıve
Healthy individuals as controls
No ocular or systemic diseases or aggressive treatments and no ocular surgery or laser for 12 months (at least);
no other oral supplements with antioxidants and/or omega 3 fatty acids
Provided written informed consent before any related activities commence
Participants able to attend the visits and to follow the study guidelines
Exclusion
Males and females, aged <25 years and >80 years
Insulin dependent patients
Ocular or systemic diseases or aggressive treatments and/or previous ocular surgery or laser
Antioxidant and/or omega 3 fatty acids supplements
No acceptance for the study participation and/or not signing the informed consent
Participants unable to attend the visits or to follow the study guidelines
mainly the omega 3 docosahexaenoic acids (DHA), which
are extremely susceptible to lipid peroxidation and protein
modifications that may be induced by the lipid peroxidation
by-products [21]. Current knowledge on the physiological
and pathological mechanisms of oxidative stress in DR has
been collected from a wide spectrum of both the animal
models research and the epidemiological studies [22, 23].
However, clinical trials have provided ambiguous results on
the effects of the antioxidant [24, 25] and PUFAs [26, 27]
supplements on the development and progression of DR.
Chronically elevated glucose/HbA1c levels altogether
with a series of endogenous and exogenous risk factors lead
to the retinopathy. The primary goal of the present study
is to investigate the risk of retinopathy in a Mediterranean
population of T2DMpatients, according to clinical, biochem-
ical, and lifestyle biomarkers, the oxidative stress status being
among them. Secondary goal was to evaluate the effects of
the oral administration of supplements with antioxidants and
omega 3 fatty acids (A/𝜔3) in the oxidative stress outcomes
and the inflammation and vascular risk biomarkers, to better
manage eye care and vision among diabetics.
2. Material and Methods
2.1. Community-Based Study Design. The study was done in
agreementwith theDeclaration ofHelsinki for human studies
(as revised in Edinburgh, 2000), and all records were treated
according to the Spanish law for protecting personal data
(LOPD: Organic Law 15/1999, de 13 Dic). Our study was
validated by the Ethics Committee and Clinical Research of
the University Hospital Dr. Peset of Valencia (Spain), the
main center of the Research Project (number 12/33), and
by the Ethics Committees of all participating institutions.
Moreover, the study received the permission of the Agencia
Espan˜ola deMedicamentos y Productos Sanitarios (AEMPS).
We conducted a prospective multicenter study lasting for
18 months (Jan 2013–June 2014) that was carried out in 10
centers by 32 investigators, with the main goal of delineating
the natural history of DM and eye disease as well as the risk
factors for DR in T2DM patients and to evaluate whether
A/𝜔3 supplements could increase compliance with the health
and vision care among diabetics.
The participant investigators were selected to obtain
stratified ophthalmologists frommain hospitals pertaining to
the National Health System in the Valencia Community and
ophthalmology clinics, as well as basic researchers involved
in ophthalmology and vision sciences.
A total of 360 persons (25–80 years old) of both
sexes were preinterviewed for eligibility for the study that
was determined by the main investigator, according to
the inclusion/exclusion criteria listed in Table 1. First point
for recruitment was the diagnosis of T2DM and the duration
of disease since diagnosis. In parallel, healthy individuals
were also recruited. Therefore, from the initial sample, 265
suitable participants were enrolled, signed the informed
consent, and were appointed to the first visit of this inter-
ventional study. Then, office visits were programmed every
six months, including periodical telephone calls from the
investigators throughout the study. Total study duration was
18 months and the characteristics of recruitment are enclosed
in Figure 1.
2.2. Patients and Methods
2.2.1. Interview. Participants who completed the first enroll-
ment interview (𝑛 = 265) were enclosed for demographics,
patient characteristics, and lifestyle. The following vari-
ables were recorded: age, sex, ethnicity, DM duration, BMI
(height, weight), familial background, current medication,
smoking/drinking habits, and physical exercise. In the mid-
twentieth century, Professor Ancel Keys observed the nutri-
tional habits of people living in the European Mediter-
ranean countries leading to the conclusion that a signifi-
cant reduction in the incidence of chronic diseases and a
higher lifespan were main characteristics of this area (for
further reading, Keys et al. The diet and 15-year death ratein
the seven countries study. Am J Epidemiol. 1986; 124:903).
Major details of this type of diet are (1) the elevated consump-
tion of fruits, vegetables, legumes, olive oil, bread, and cereals,
(2) the moderate-to-high ingestion of fish and chicken meat,
(3) the moderate intake of cheese, yogurt, and wine, and
(4) the low levels of consumption of red meat. The UNESCO
raised the Mediterranean diet in 2013 as a lifestyle in itself
and a cultural heritage for the humanity. We used a 14-item
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T2 diabetics: T2DMG (n = 210) Controls: CG (n = 150)
Interview: personal and familial characteristics and lifestyle
Ophthalmological examination
Best corrected visual acuity
Ocular fundus examination and photographs
Optical coherence tomography
Classification: degree of diabetic retinopathy
CG
18 months of follow-up (n = 208)
Eligibility decision, accepting to participate, informed consent (n = 265)
Persons attending the department of ophthalmology of the study centers (n = 360)
Subclassification according to antioxidants/omega 3 fatty acids
T2DR+DR
T2DR−DR
T2DR+DR+A𝜔3
T2DR+DR−A𝜔3
T2DR−DR+A𝜔3
T2DR−DR−A𝜔3
CG+A𝜔3
CG−A𝜔3
Figure 1: Flowchart of the challenges for the recruitment and screening methods of the study participants: characteristics of recruitment,
sample size, and study design.
questionnaire to assess the adherence of the sample partic-
ipants with the Mediterranean diet (AMD). The Mediter-
ranean diet scores indicating compliance to the Mediter-
ranean diet distinguished between the participants with a
high intake of cereals, legumes, fruits, vegetables, olive oil,
fish, bread, and red wine that were scored positive (1), while
those with a low intake of these meals were scored negative
(0). The results of this questionnaire were reflected as par-
ticipants having either good adherence to the Mediterranean
diet (GAMD) or poor adherence to the Mediterranean diet
(PAMD).
The T2DMG (𝑛 = 165) was subclassified according to
having or not having DR. Furthermore, each of these sub-
groups was homogeneously subdivided into those partici-
pants that were randomly assigned to take or not one pill
per day of the A/𝜔3 supplementation (T2DMG+DR+A/𝜔3/
T2DMG+DR−A/𝜔3; and T2DMG–DR+A/𝜔3/T2DMG–
DR−A/𝜔3). The CG (𝑛 = 100) was also randomly assigned
to those taking (CG+A/𝜔3) or not (CG−A/𝜔3) the A/𝜔3
supplements. A flow chart with the number of patients per-
taining to the groups and subgroups is enclosed in Fig-
ure 1.The nutraceutic formulation contains docosahexaenoic
acid (DHA), vitamins (E, C, B1, B2, B3, B6, B9, and B12),
lutein, zeaxanthin, glutathione, hydroxytyrosol, and trace
elements (Se, Mn, Zn, and Cu), commercialized as Nutrof
Omega, commercialized by Laboratorios Thea SA (Barce-
lona, Spain) that gently provided all the oral supplementation
needed for the study participants. The study-related visits
and the nutraceutic supplements (Nutrof Omega) were given
to our participating volunteers (randomly chosen) without
any charge.
2.2.2. Ophthalmic Examination. A systematized ophthalmo-
logical examination was performed to our 265 participants
including best corrected visual acuity (BCVA) with each
eye, ocular fundus examination and retinographs (ImageNet;
Topcon, Barcelona, Spain), and optic coherence tomogra-
phy (OCT) examination (Spectral Domain SD-OCT; Zeiss,
Madrid, Spain).
TheDR diagnosis was done from ocular fundus examina-
tion and photographs which were carried out in each eye of
the T2DG (𝑛 = 165), based on the Early Treatment of Dia-
betic Retinopathy Study (ETDRS), and the DR severity was
graded as described before [28]. The presence and number
of microaneurysms, hemorrhages, venous beading, and/or
intraretinal microvascular abnormalities were considered the
most relevant factors for monitoring DR progression. In
fact, retinopathy worsened basically by overall augment in
counts of microaneurysms and haemorrhages. The ETDRS
retinopathy severity scale divides the process into 13 levels
ranging from absence of retinopathy to severe vitreous
hemorrhage.
The OCT parameters were measured with the Cirrus SD-
OCT direct cross-sectional imaging device of Zeiss Meditec
(Dublin, CA, USA) in a total of 265 eyes with the clinical
diagnosis of nonproliferative diabetic retinopathy (T2DG;
(𝑛 = 165) with or without DR and/or clinically significant
macular edema) and in the healthy participants (CG; 𝑛 =
100). Prior to the OCT examination, each participant was
administered a drop of tropicamide in both eyes to dilate the
pupils. Each ophthalmologist visualized the representative A-
scan and manually moved the measurement cursors (first at
the signal that represents the internal limitingmembrane and
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second at the signal that denotes the retinal pigment epithe-
lium). Then, the most profound zone of the foveal pit was
taken as the center. Six consecutive scans were performed for
each eye. Cross-sectional retinal images were optimized for
each scan to obtain the highest intensity/definition; therefore
these scans with signal strengths ≥ 7 and without artifacts
were included in this study. Briefly, acquisition protocols
were macular cube 200 × 200; HD 5 line raster/5 raster
line; and HD one line. The raw OCT datasets were exported
to a personal computer for analysis. The SD-OCT system
analyzed retinal thickness, creating a topographic map and
graphs for quantitatively and qualitatively documenting any
changes in retinal thickness and edema. Main exclusion
criteria for this technique were any retinal pathology other
than DR or opaquemedia such as in cataracts and inability to
undergo the OCT examination due to mobility or cognitive
difficulties.
2.2.3. Sample Processing. At baseline and every 6 months of
the follow-up, all participants were visited in the correspond-
ing centers and the peripheral blood was collected from the
antecubital vein under fasting conditions (between 8:00 and
9:00 a.m.). Part of the obtained blood tubes was analyzed by
computerized systems to determine laboratory blood draws
and analysis: glucose, glycosylated hemoglobin (HbA1c),
cholesterol (HDL, LDL), and triglycerides. Two more EDTA
tubes were obtained and transported in optimal conditions
for preservation to the ophthalmic research centers. Each
blood sample was centrifuged at 3000 rpm for 10min and
the plasma and erythrocytes were separated into Eppendorfs,
labeled, and registered to be stored at −80∘C until processing,
as described below.
(1) Determination of Malondialdehyde- (MDA-) Thiobarbi-
turic Acid Reactive Substances (TBARS). Thiobarbituric acid
reactive substances (TBARS) includingMDAwere measured
in plasma samples, as lipid peroxidation by-products. Briefly,
at high temperature (90–100∘C) under acidic conditions
MDA-TBA complex was formed by the reaction between
these molecules and extracted with butanol, according to
previous descriptions [28, 29]. The fluorescence of these
complexes was measured in duplicate at 544 nm excitation
and 590 nm emission deep, relative to the fluorescence of the
standard samples, and then the concentration of the samples
was calculated by extrapolating the results in the standard
curve.
(2) Total Antioxidant Activity (TAA). The antioxidant activity
was measured in the plasma samples by means of the
antioxidant assay (Cayman Chemical Company, Ann Arbor,
MI) commercial kit. The kit is based on the antioxidant
capacity of plasma to inhibit the oxidation of ABTS (2,2󸀠-
azino-di-[3-ethylbenzthiazoline sulphonate]) to ABTS+ by
the metmyoglobin, as previously reported [30, 31].
2.3. Statistical Procedures. For statistical analysis, the excel
program and the SPSS 15.0 (SPSS Inc., Chicago, IL, USA)
were used. All the programmed experiments were performed
in duplicate for each sample. The continuous variables were
Table 2: Sociodemographic characteristics of diabetics with/with-
out retinopathy.
T2DM+DR T2DM−DR 𝑝∗
Age (years) 65.1 ± 8.6 62.3 ± 10.1 0.094
Gender (% of women) 52.7 48.6 0.645
DM duration (years) 19.2 ± 6.8 10.4 ± 7.1 <0.001∗
Physical exercise (%) 27.3 45.7 0.035∗
Smoking (%) 43.6 15.7 0.002∗
Alcohol drinking (%) 38.2 8.6 <0.001∗
BMI (kg/m2) 28.8 ± 4.6 28.0 ± 4.0 0.345
GAMD (%) 18.2 44.3 0.002∗
T2DM+DR: type 2 diabetes mellitus with diabetic retinopathy; T2DM−DR:
type 2 diabetes mellitus without diabetic retinopathy; DM: diabetes mellitus;
BMI: bodymass index; GAMD: good adherence toMediterranean diet. Data
are shown as mean ± standard deviation.
∗Statistically significant (𝑝 < 0.05).
expressed as mean ± standard deviation of the mean (SD).
Categorical variables were expressed as percentages. The sta-
tistical test performedutilized the two/tailed test at 5% level of
significance. Appropriate analysis of covariance models was
also performed.
3. Results
From the initial suitable participants (𝑛 = 265), a total of 208
participants (130T2DMpatients (62+DRversus 68−DR) and
78 healthy controls) continued and completed altogether the
18 months of the study.
Demographics, patient characteristics, and lifestyle
details of the study participants are listed in Table 2. It has
to be emphasized that the HBP was twice frequent in the
T2DMG+DR than in the diabetics −DR (𝑝 < 0.001).
The BCVA (each eye in separate) was lower in the
T2DMG than in the CG [(CG at baseline: RE: 0.95 ± 0.10 and
LE: 0.96 ± 0.08; 𝑝 < 0.001/CG; at 18 months: RE: 0.95 ± 0.11
and LE: 0.95 ± 0.10; 𝑝 < 0.001) (T2DMG at baseline: RE:
0.81 ± 0.30 and LE: 0.83 ± 0.22; 𝑝 < 0.001/T2DMG; at 18
months: RE: 0.78 ± 0.22 and LE: 0.76 ± 0.22; 𝑝 < 0.001)].
The baseline ocular fundus examination revealed that
62 patients of the T2DMG displayed DR with the following
degrees of severity: 63.6%: mild DR, 29.1%: moderate DR,
and 7.3%: severe DR. From baseline to the end of study, 11
patients remained without signs of DR progression, but the
rest progressed as follows: 29.1% displayed mild DR, 36.4%
moderate DR, and 14.5% severe DR. Furthermore, the 68
T2DMG patients that did not have DR showed progression
of disease at the end of study in the following proportions:
14.3% of the patients without DR progressed to mild DR,
7.1% of the patients without DR progressed to moderate DR,
and no progression to severe degree of DR was detected
through the follow-up in any of these patients. In our study,
the T2DMGdisplayedDME (clinically significant) at baseline
5.6% DME in the RE versus the 11.2% in the LE (𝑝 =
0.037, 𝑝 = 0.003, resp.). Moreover, DME was more frequent
in the T2DMG+DR than in the T2DMG−DR and the CG
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+A/𝜔3 +A/𝜔3 −A/𝜔3−A/𝜔3
+onset/progression of DR
−onset/progression of DR
Onset/progression of retinopathy in type-2
diabetic patients after 18 months of follow-up
61%
39%
92%
8% 9%
91%
35%
65%
T2DM+DR T2DM−DR
Figure 2: Percentages of development or progression of DR in the
participants during the study course, according to being assigned
or not to the oral supplementation. +A/𝜔3: oral supplementation
with antioxidants and omega 3 fatty acids. –A/𝜔3: without taking the
oral supplementation. T2DM+DR: type 2 diabetics with retinopathy.
T2DM−DR: type 2 diabetics without retinopathy.
(𝑝 = 7.036𝐸−005 for the RE and 𝑝 = 2.214𝐸−006 for the LE).
At the end of study, it was seen that DME was significantly
more frequent in patients with severe DR (50%) than in those
with mild or moderate DME (𝑝 = 0.03). A summary of the
progression characteristics based on the ocular fundus and
SD-OCT examination of the study participants is reflected in
Figure 2.
All the results obtained from the ophthalmic examination
of the study participants are enclosed in Table 3.
Classical and oxidative stress hematologic parameters
from the T2DM participants are enclosed in Table 4. Para-
meters related to oxidative stress (lipid peroxidation
(MDA/TBARS), total antioxidant activity (TAA)) showed
that the plasmatic MDA/TBARS levels were significantly
higher, and the TAC was significantly lower in diabetics as
compared to the CG (Table 4). It was also observed that the
MDA/TBARS displayed significantly higher concentrations
and the TAA showed significantly lower activities in the
T2DMG+DR with respect to those diabetics without DR and
the CG (Table 4). Data from the oxidative stress parameters
according to the degree of severity of DR (ETDRS inter-
national scale) are reflected in Table 5. The MDA/TBARS
levels augmented with DR progression, but the TAA signifi-
cantly decreased with DR progression.
The adherence to theMediterranean diet nutritional facts
of the study participants were reflected in the 14-item ques-
tionnaire. Specifically, average values for the 14-item score
were significantly higher in the CG (9.8 ± 2.0) versus the
T2DMG (6.4 ± 1) (𝑝 < 0.05). The comparison of the pro-
oxidant and antioxidant markers analyzed in the present
study in the T2DMG with poor and good adherence to the
Mediterranean diet (PAMD/GAMD) is reflected in Table 6.
When assessing the oxidative stress status at the end
of the eighteen months of the follow-up, it was seen that
plasmatic MDA/TBARS levels significantly decreased in the
T2DM+A/𝜔3 subgroup with respect to the T2DM−A/𝜔3
Table 3: Ophthalmic examination records of the study participants.
T2DM
BCVA RE
Baseline 0.81 ± 0.296
18 months 0.78 ± 0.220
𝑝 value 0.176
BCVA LE
Baseline 0.83 ± 0.22
18 months 0.78 ± 0.22
𝑝 value 0.388
IOP RE (mmHg)
Baseline 15.2 ± 2.8
18 months 15.6 ± 2.5
𝑝 value 0.099
IOP LE (mmHg)
Baseline 15.6 ± 2.9
18 months 16.1± 2.5
𝑝 value 0.048∗
RNFLT RE (𝜇m)
Baseline 251.65 ± 22.79
18 months 254.14 ± 31.60
𝑝 value 0.001∗
RNFLT LE (𝜇m)
Baseline 258.53 ± 55.029
18 months 262.22 ± 6.38
𝑝 value 0.011∗
MT RE (𝑛) Baseline 5.6% (13)
18 months 7.2% (9)
MT LE (𝑛) Baseline 11.2% (14)
18 months 10.4% (13)
DM − R: diabetes mellitus without retinopathy; DM + R: diabetes mellitus
with retinopathy; BCVA: best corrected visual acuity; RE: right eye; LE: left
eye; IOP: intraocular pressure; RNFL: retinal nerve fiber layer thickness;MT:
macular thickness. Data are shown as mean ± standard deviation.
∗Statistically significant (𝑝 < 0.05).
patients (Figure 3(a)). Furthermore, the TAC significantly
increased in the T2DM+A/𝜔3 subgroup, while the nonsup-
plemented participants did not show any noticeable change
(Figure 3(b)).
4. Discussion
The retinopathy is the major cause of blindness among adult
diabetics (aged 20–75 years) in the developed world [1–
6]. In this population-based multicenter study carried out
in 265 participants from the Mediterranean area of Spain
(T2DMG; 𝑛 = 165 versus CG; 𝑛 = 100), “The Valencia
Study on Diabetic Retinopathy (VSDR),” we have identified
significant risk factors of DR, such as theHBP, duration of the
DM, physical exercise, the BMI, the smoking/drinking habits,
the dyslipidemia, and the oxidative stress. In fact, plasmatic
oxidative stress biomarkers increased and antioxidant activity
decreased in the diabetics with DR, with respect to those
without DR and the healthy controls, data consistent with
previous reports fromour group andother authors [18, 19, 22–
25]. More precise information about each of these risk factors
is provided below.
The HBP was present in 76.4% of our T2DM+DR versus
58.6% of the T2DM−DR and 9.3% of the CG (𝑝 < 0.001).
Emdin et al. [32] studying patients with T2DM emphasized
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Table 4: Haematologic parameters in diabetics with/without retinopathy at baseline and at 18 months of follow-up.
T2DM−DR
𝑝
T2DM+DR
𝑝
Baseline End of study Baseline End of study
MDA (𝜇m/L) 2.37 ± 1.39 2.43 ± 0.98 0.724 3.63 ± 1.30 3.83 ± 1.81 0.482
TAS (𝜇M) 2.64 ± 1.52 2.87 ± 1.31 0.203 1.96 ± 1.32 2.09 ± 1.39 0.020∗
HbA1c (%) 7.12 ± 1.55 6.99 ± 1.30 0.307 7.87 ± 1.48 8.72 ± 1.45 0.046∗
Total-c (mg/mL) 186.8 ± 39.4 184.3 ± 37.6 0.669 178.8 ± 32.6 181.3 ± 33.8 0.522
HDL-c (mg/mL) 50.4 ± 13.1 51.6 ± 14.2 0.479 51.5 ± 13.0 51.4 ± 13.0 0.959
LDL-c (mg/mL) 104.3 ± 28.6 102.3 ± 35.2 0.687 99.9 ± 29.4 102.6 ± 35.4 0.587
DM − R: diabetes mellitus without retinopathy; DM + R: diabetes mellitus with retinopathy; MDA: malondialdehyde; TAS: total antioxidant status; HbA1c:
glycosilated hemoglobin; total-c: total-cholesterol; HDL-c: higher density lipoprotein-cholesterol; LDL-c: lower density lipoprotein-cholesterol. Data are shown
as mean ± standard deviation.
∗Statistically significant (𝑝 < 0.05).
Malondialdehyde (𝜇m/L)
Baseline End of study
⋆
4.5
4
3.5
3
2.5
2
1.5
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T2DR−A/𝜔3
(a)
Baseline End of study
4.5
4
3.5
3
2.5
2
1.5
1
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Total antioxidant activity (𝜇M)
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−A/𝜔3
(b)
Figure 3: Oxidative and antioxidant status in the type 2 diabetics during the 18months of follow-up, according to being assigned or not to the
oral supplementation of A/𝜔3 supplements. T2DR+A/𝜔3: type 2 diabetics with retinopathy taking the oral supplementation; T2DR−A/𝜔3:
type 2 diabetics with retinopathy not taking the oral supplementation; +A/𝜔3: assigned to the oral supplementation; −A/𝜔3: not assigned to
the oral supplementation.
Table 5: Oxidative status in diabetics according to the degree of
retinopathy (ETDRS International scale).
T2DMG MDA/TBARS (𝜇mol/L) TAA (𝜇mol/L)
−DR 1.19 ± 0.53 3.84 ± 1.24
+DR
Mild DR 3.00 ± 1.74 2.38 ± 1.30
Moderate DR 4.94 ± 1.29 1.29 ± 0.59
Severe DR 5.36 ± 0.51 1.10 ± 0.34
𝑝 value∗ 2.997𝐸 − 006∗∗ 4.857𝐸 − 005∗∗
−DR: diabetes mellitus without retinopathy; +DR: diabetes mellitus with
retinopathy; MDA: malondialdehyde; TAA: total antioxidant activity. Data
are shown as mean ± standard deviation.
∗
𝑝 value obtained from ANOVA analysis.
∗∗Statistically significant (𝑝 < 0.05).
that appropriated HBP lowering was related to improved
mortality and other positive clinical changes in the affected
patients. Barrios and Escobar [33] reported that DM and
HBP are closely related disorders creating an optimum
background for atherosclerosis. In fact, the strict control
of both processes is pivotal to ameliorate macroangiopa-
thy/microangiopathy prognosis in the affected patients.
The lead time between the diagnosis of the disease and the
first appointment for the present study was considered as the
duration of DM. Average DM durability in our participants
was 14.2 ± 8.2 years. Furthermore, in the T2DMG+DR, it
was 19.2 ± 6.8 years while in those without retinopathy
the duration of DM was 10.4 ± 7.1 years. In our work this
parameter was also related to the degree of severity of DR,
as shown in Table 5. We demonstrated that the duration of
DM was strongly associated with a higher risk of retinopathy
(OR = 1.18 𝑝 < 0.001). Other authors also reported a
strong relationship between DM duration and retinopathy,
neuropathy, nephropathy, and peripheral vasculopathy in a
sample of 1,157 individuals of Northwest India [34].
Healthy participants performing physical exercise
accounted for almost double than the diabetics (CG: 68%
versus T2DMG 37.6%; 𝑝 < 0.001). Regarding the presence
8 BioMed Research International
Table 6: Comparison of the plasmatic prooxidant and antioxidant markers found in the diabetes mellitus patients according to having
poor/good adherence to Mediterranean diet.
T2DM−DR T2DM+DR
𝑝
∗
PAMD GAMD PAMD GAMD
MDA1 (𝜇m/L) 2.30 ± 1.14 2.47 ± 1.67 3.77 ± 1.26 3.01 ± 1.32 <0.001a,b
MDA2 (𝜇m/L) 2.32 ± 0.85 2.58 ± 1.11 4.12 ± 1.78 2.49 ± 1.31 <0.001a,b,c
TAA1 (𝜇M) 2.57 ± 1.50 2.71 ± 1.58 1.86 ± 1.10 2.39 ± 2.06 0.051
TAA2 (𝜇M) 3.11 ± 1.50 2.58 ± 0.99 1.91 ± 1.38 2.88 ± 1.17 0.001a
T2DM−RD: type 2 Diabetes mellitus patients without diabetic retinopathy; T2DM+DR: type 2 diabetes mellitus patients with diabetic retinopathy; PAMD:
poor adherence to Mediterranean diet; GAMD: good adherence to Mediterranean diet; MDA1: malondialdehyde-baseline; MDA2: malondialdehyde-end of
study; TAA1: total antioxidant activity-baseline; TAA2: total antioxidant activity-end of study. Data are shown as mean ± standard deviation.
∗
𝑝 value obtained from ANOVA analysis.
a: significant differences between DM − DR PAMD and DM + DR PAMD; b: significant differences between DM − DR GAMD and DM + DR PAMD; c:
significant differences between DM + DR PAMD and DM + DR GAMD.
of retinopathy, significantly higher percentage of subjects
performing physical exercise was observed in T2DMG−DR
than in the T2DMG+DR (45% versus 27%; 𝑝 = 0.035). Our
results coincide with those reporting that physical exercise is
beneficial with respect to both the glycemic control and the
diabetes-related comorbidities, including the vitreoretinal
disorders [35].
The importance of data regarding the BMI from our
participants was notorious. Significant differences between
the CG and the T2DMG (13.8 + 3.8 kg/m2 versus 28.4 +
4.3 kg/m2; 𝑝 < 0.001) were detected. When the presence of
retinopathy was analyzed, it was seen that the differences of
BMI between the T2DMG+DR and T2DMG−DR were not
significant (28.8 + 4.7 kg/m2 versus 28.0 + 4.0 kg/m2; 𝑝 =
0.345). In agreement with these data, it has been reported
that BMI in correlation with HbA1c, HBP, and cholesterol
seems to be related to DR progression in T2DM patients
[36]. Furthermore, it has been suggested that BMI may be
considered as a predictive marker for the development and
progression of DR [36, 37]. In addition to the carbohydrate
restriction, dietary recommendations on this topic include
saturated fat restriction (<7% of daily caloric intake) and
cholesterol restriction (<200mg/dL) among diabetics.
Tobacco use is a major cause of disease, disability, and
premature death worldwide. Our results showed a higher
frequency of smokers among the T2DMG than in the CG
(34.4% versus 20%, resp.; 𝑝 = 0.03). Diabetics also displayed
higher alcohol consumption than the healthy participants
(24.8% versus 17.3%) but the difference was not statistically
significant (𝑝 = 0.217). Furthermore, the T2DMG+DR
showed significant differences regarding tobacco and alcohol
consumption with respect to the T2DMG−DR (𝑝 = 0.001
and 𝑝 < 0.001, resp.). In fact, it has been described that
drinking in excess has to be avoided because it induces
ketoacidosis and hypertriglyceridemia. Moreover, it has to be
emphasized that alcohol taken outside the meals can cause
hypoglycemia crisis and a relevant increase of a host of health
problems [38, 39].
Oxidative stress, affecting the cell and tissue morphology
and functions, as well as leading to cell death, is amajor player
in the pathogenesis of a wide variety of retinal diseases. This
fact called our attention regarding DR, because knowledge
on the precise molecular mechanisms of DR development
and progression is far from complete. Up to date, there is
no definitive treatment for the disease. In the Mediterranean
Spanish region of Valencia, 500.000 diabetics (from a total
of 5.004.844 inhabitants) have been recorded in the last year.
Blood samples from our diabetics were analyzed for the
oxidative and antioxidant activities, as well as for determining
the glycemia, HbA1, HDL/LDL cholesterol, and triglycerides.
Despite the classical parameters that were significantly higher
in diabetics (glycemia, HbA1C), as expected, it was quite
surprising that the triglycerides levels were significantly
lower in the CG than in the T2DMG at baseline (97.5 ±
59.8mg/dL versus 149.6 ± 96.6mg/dL; 𝑝 < 0.001) and after
18 months (114.7 ± 69.3mg/dL versus 142.6 ± 80.9mg/dL;
𝑝 = 0.014). However, this data was not statistically significant
between the diabetics with/without DR at baseline (133.63 ±
65.16mg/dL versus 156.86 ± 114.85mg/dL; 𝑝 = 0.385)
neither after 18 months (134.0 ± 65.9mg/dL versus 141.3 ±
91.0mg/dL; 𝑝 = 0.812). Other authors concluded that no
significant association between DR, triglycerides, HDL, and
total cholesterol was detected in a sample of Danish diabetics
[40]. Miljanovic et al. did not find associations between
lipid profile and DR progression [41]. In contrast, the global
case-control study in 13 countries concluded that DR was
associated with triglycerides and high-density lipoprotein
cholesterol in matched analysis [42].
It has been widely recognized that MDA/TBARS are
associated with the production of AGEs implicated in the DR
development. This mechanism is mainly due to AGEs accu-
mulation in the ocular tissues by increasing cell permeability,
angiogenesis, and disruption of the internal blood-retinal
barrier [43]. PlasmaticMDA/TBARS levels were significantly
higher and the TAA levels were significantly lower in the
T2DMG than in the CG. Furthermore, the oxidative status
was significantly higher and the antioxidant activity was
significantly lower in diabetics +RD with respect to dia-
betics −RD, data similar to previous reports demonstrating
enhanced oxidative stress in T2DM patients [16–19, 23, 28].
Interesting results came from the relationship between the
DR degree of severity and the plasmatic oxidative stress
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markers, pointing to the fact that the prooxidants signifi-
cantly increased and the antioxidants significantly decreased
in plasma samples of the T2DMG according to the ETDRS
severity scale, as shown in Table 5. Data strongly suggests
that the hyperglycemia created a particular oxidative stress
background in the retina of the participant diabetics that, in
turns, influences the onset and progression ofDR, as reflected
throughout the 18 months of the follow-up.
We also observed that a nutraceutic formulation con-
taining A/𝜔3 is capable of counteracting the oxidative stress
detected in this diabetic Mediterranean population, as
reflected in Figure 2 and Tables 4–6. In addition to the anti-
oxidant enzymes, the robust antioxidant capacities of a
high variety of nonenzymatic antioxidants—among them
are vitamins (ascorbic acid (vit C), 𝛼-tocopherol (vit E)),
transition metals (selenium (Se), zinc (Zn), copper (Cu),
and manganese (Mn)), glutathione, carotenoids (𝛽-carotene,
lutein, and lycopene), hormones (melatonin, oestrogen),
phenols (catechin, quercetin), and so forth—and the added
benefits of the antioxidant and anti-inflammatory properties
of the PUFAs are well defined in the literature [21, 22,
24–27]. Therefore, possible protecting mechanisms against
oxidative stress of the oral supplementation with a combi-
nation of A/𝜔3 in our diabetics may include a mixture of
the strong antioxidant activity from vitamins C and E, the
carotenoids lutein and zeaxanthin, the free radical scavenging
glutathione, and the trace elements Se, Zn, Cu, and Mn,
as well as the DHA and DHA-metabolic by-products, all
of which are participating in scavenging excessive oxidants,
preventing free radical generation, recycling other antiox-
idants, and probably ameliorating the mitochondrial func-
tions (oxidative phosphorylation). In this framework, it has
been reported that systemic interventions are highly required
for controlling DR patients. Among these, early detection
of hyperglycemia and intensive glycemic control together
with hypertension and dyslipidemia therapy have to be
programmed. As a consequence of the results raised during
this study course, strategies for avoidingDRdevelopment and
progression should therefore aim to prevent specifically the
effects of glycation but also the oxidative stress consequences.
Therefore, it is reasonable to consider that biotherapies with
multiple targets can be more useful than unique drugs in DR
treatment [43].
However, it is notorious that studies with oral supple-
ments on DR have yielded conflicting findings. Among the
studies on the role of A/𝜔3 in the prevention of DR, the
San Luis Valley Diabetes Study did not find protective effect
in DR and vitamin E on DR of the b-carotene, vitamin
C, and vitamin E [44]. The Third National Health and
Nutrition Examination study described that 𝛼-tocopherol
and vitamin C serum levels were not associated with DR
[45].Moreover, theDiabetesControl andComplicationsTrial
described that patients assigned to a low-fat diet decreased
the rate of DR progression as compared with patients not
following the low-fat diet [46]. In addition, antioxidant and
antiangiogenic properties of edible berries were shown to be
protective for DR [47]. Garc´ıa-Medina et al. [48] designed
a follow-up study in the Mediterranean area of Spain in
T2DM patients with nonproliferative diabetic retinopathy,
evaluating the effect of A/𝜔3 supplementation over a 5-year
follow-up. The DR stage showed a retardation of progression
in the subgroup with supplementation but worsened in
the nonsupplemented subgroup. It was also described that
the oral supplements maintained the antioxidant defenses
activity as shown by the high plasmatic TAA levels, which
was related to the decreased oxidative plasma activity. In
several experimental studies using different strains, it was
shown that increasing the diversity of antioxidants provides
significantly more protection than using a single antioxidant
for the supplementation. Moreover, when antioxidants were
administered to diabetic rats with the main goal of assessing
the ability of these agents to inhibit the development of
DR, the authors concluded that long-term administration
of antioxidants could inhibit the development of the early
phases of DR [49]. Hence, the oral supplementation with
A/𝜔3 represents an achievable adjunct to help preserve vision
in diabetics.
It is recognized that proliferative diabetic retinopathy
(PDR) is the most usual sight-threatening vitreoretinal dam-
age in T1DM patients, while diabetic macular edema (DME)
is considered the main cause of visual impairment and
blindness in the T2DM patients [50, 51]. In our study, the
T2DMG displayed DME (clinically significant) at baseline
5.6% DME in the RE versus the 11.2% in the LE (𝑝 = 0.037,
𝑝 = 0.003, resp.). Moreover, DME was more frequent in
the T2DMG+DR than in the T2DMG−DR and the CG (𝑝 =
7.036
𝐸−005 for the RE, and 𝑝 = 2.214𝐸−006 for the LE). Among
the recognized risk factors are the hyperglycemia, HBP, dys-
lipidemia, DMduration, and oxidative stress status. However,
our study supports the benefits of the A/𝜔3 supplements
as well as the important modifiable component for the risk
factors profile for better managing the diabetic eyes and
vision.
One additional interesting aspect of our work is that
compliance with the Mediterranean diet was assessed by a
brief 14-item validated questionnaire which is faster and less
complicated to the participants than other questionnaires,
being considered very useful by the investigators [52, 53].
The Mediterranean diet is a nutritional and lifestyle pattern
based on the traditional dietary habits of Greece, Italy, and
Spain [52]. The term Mediterranean diet was set by Ancel
Keys in 1960. In our study course, we have detected that
the average values of the 14-item Mediterranean diet scores
were significantly higher in the CG versus the T2DMG
(𝑝 < 0.05). Moreover, comparison of the prooxidant and
antioxidant markers in the T2DMG with GAMD or PAMD
also reported significant differences (Table 6). These results
point to those people with GAMD with the above described
dietary habits who had a lesser risk of DR, which agree with
previous reports regarding the lesser risk of chronic and
cardiovascular diseases among the Mediterranean countries
inhabitants [50–52]. At this point, we may suggest that this
type of questionnaire is useful for evaluating the role of the
Mediterranean diet in the ocular diseases.
A limitation of this study was the relatively small sample
size of 265 participants at baseline (T2DMG; 𝑛 = 165 versus
CG; 𝑛 = 100) and the important patients lost to follow-up
(a total of 208 participants—among them are 130 patients
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from the T2DMG (62 +DR versus 68 −DR) and 78 healthy
individuals from the CG—continued and completed alto-
gether the 18 months of the study). For this reason, these
findings are helpful enough to understand the characteristics
of the studied population, but we are trying to control these
important variables for further research, to better generalize
our results to the broader community.
5. Conclusions
Healthy living includes everything we have to plan for
improving our wellbeing. Specifically, diabetics have to be
able to handle life’s challenges, including exercise, being aware
of smoking and drinking in excess, andmaintaining the body
weight. All of these have to be considered key milestones
for eye care in diabetics. The DM induced an oxidative
background in T2DM participants of the Mediterranean
study area that was enhanced in patients +DR. The A/𝜔3
formulation utilized herein provided the appropriate vita-
mins, minerals, and PUFAs, resulting in decreased plasmatic
oxidative level and increased antioxidant activity in diabetics.
Antioxidant supplementation may be useful to help manage
diabetics at risk of retinopathy and vision loss.
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